サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1693366

神経栄養性角膜炎治療の世界市場レポート 2025年

Neurotrophic Keratitis Treatment Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.32円
神経栄養性角膜炎治療の世界市場レポート 2025年
出版日: 2025年03月04日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経栄養性角膜炎治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年には73億9,000万米ドルに成長し、CAGRは7.6％となります。予測期間の成長は、教育イニシアティブ、臨床試験の増加、先進治療、規制当局の承認に起因すると考えられます。予測期間の主な動向には、診断ツールの改善、デジタルヘルスソリューション、神経保護戦略、高度な眼表面画像化などがあります。

眼疾患の有病率の増加は、今後数年間の神経栄養性角膜炎治療市場の成長を促進すると予想されます。眼疾患には、眼の構造や機能に影響を及ぼすさまざまな疾患が含まれます。神経栄養性角膜炎治療は、角膜感覚の改善、治癒の促進、感染の予防、痛みの緩和に役立ちます。例えば、2022年3月、米国を拠点とするアイケアキャリア開発プラットフォームであるEye Care Oneは、2022年には米国で推定3,500万人がドライアイ（DED）に罹患しており、有病率は年々上昇する見込みであると報告しました。さらに2024年5月、保健福祉省傘下の米国連邦政府機関である疾病対策予防センター（CDC）は、40歳以上の米国人のうち340万人以上が失明または視覚障害者であり、その数は2030年までに倍増すると予測していると発表しました。このように、眼疾患の有病率の増加が神経栄養性角膜炎治療市場の拡大を牽引しています。

ヘルスケア、特に眼科医療への投資の拡大が、今後の神経栄養性角膜炎治療市場の成長を牽引すると予想されます。眼科医療を含むヘルスケアへの投資とは、医療サービスや治療法の開発、改善、アクセシビリティの向上に割り当てられる財源を指し、特に視覚関連の健康問題に焦点が当てられています。このような投資は、神経栄養性角膜炎の治療を前進させ、治療法、医薬品開発におけるブレークスルーをもたらし、最終的には患者の転帰とQOLを改善する上で極めて重要な役割を果たすことができます。例えば、2022年3月、オーストラリア政府の保健・高齢者医療省（Department of Health and Aged Care、保健研究と資金を監督する部門）は、保健システムへの政府投資が2022-23年には1,320億米ドルに達し、2025-26年には1,400億米ドルに増加し、今後4年間で総額5,370億米ドルになるとの予測を報告しました。したがって、眼科医療を含むヘルスケア投資の増加が神経栄養性角膜炎治療市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の神経栄養性角膜炎治療市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の神経栄養性角膜炎治療市場：成長率分析
  • 世界の神経栄養性角膜炎治療市場の実績：規模と成長、2019～2024年
  • 世界の神経栄養性角膜炎治療市場の予測：規模と成長、2024～2029年、2034年
  • 世界の神経栄養性角膜炎治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の神経栄養性角膜炎治療市場：治療法別、実績と予測、2019～2024年、2024～2029年、2034年
  • 局所抗生物質
  • 組み換えヒト神経成長因子（rhNGF）
  • 羊膜移植
  • 角膜移植
  • その他
  • 世界の神経栄養性角膜炎治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
  • 経口
  • 局所
  • その他
  • 世界の神経栄養性角膜炎治療市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
  • ステージI
  • ステージII
  • ステージIII
  • 世界の神経栄養性角膜炎治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • ホームケア
  • 専門クリニック
  • その他
  • 世界の神経栄養性角膜炎治療市場：局所抗生物質のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 広域抗生物質
  • 狭域抗生物質
  • 世界の神経栄養性角膜炎治療市場：組み換えヒト神経成長因子（rhNGF）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • セネゲルミン点眼液
  • その他のrhNGFベースのソリューション
  • 世界の神経栄養性角膜炎治療市場：羊膜移植のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 凍結保存羊膜
  • 脱水処理羊膜
  • 世界の神経栄養性角膜炎治療市場：角膜移植のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 全層角膜移植
  • 層状角膜移植
  • 世界の神経栄養性角膜炎治療市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 瞼板縫合術
  • 治療用コンタクトレンズ

第7章 地域別・国別分析

  • 世界の神経栄養性角膜炎治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の神経栄養性角膜炎治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 神経栄養性角膜炎治療市場：競合情勢
  • 神経栄養性角膜炎治療市場：企業プロファイル
    • Eyevance Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
    • Grand Pharma Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Walgreen Co. Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Bayer AG
  • Novartis AG
  • Abbott Laboratories
  • Gilead Biosciences Inc.
  • Merck and Co. Inc.
  • Allergan Inc.
  • Alcon Inc.
  • Bausch Health Companies Inc.
  • Bausch & Lomb Inc.
  • CooperVision Inc.
  • Rohto Pharmaceutical Co. Ltd.
  • Santen Pharmaceutical Co. Ltd.
  • Zhejiang Conba Pharmaceutical Co. Ltd.
  • Glenmark Pharmaceuticals Limited
  • Dompe farmaceutici S.p.A

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 神経栄養性角膜炎治療市場2029：新たな機会を提供する国
  • 神経栄養性角膜炎治療市場2029：新たな機会を提供するセグメント
  • 神経栄養性角膜炎治療市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r28606

Neurotrophic keratitis treatment is a method aimed at addressing a rare eye condition resulting from damage to the trigeminal nerve, leading to reduced corneal sensation and potential corneal harm. The objective of this treatment is to safeguard the cornea, facilitate recovery, alleviate symptoms, and prevent further damage. aimed at addressing a rare.

The main approaches of neurotrophic keratitis treatment are employed in neurotrophic keratitis treatment, including topical antibiotics, recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, keratoplasty, among others. Topical antibiotics are antimicrobial drugs administered directly to the skin or mucous membranes. They can be administered through various routes, such as oral, topical, and others, catering to stages I, II, and III of neurotropic keratitis. These treatments are utilized by different end-users, including hospitals, homecare, specialty clinics, among others.

The neurotrophic keratitis treatment market research report is one of a series of new reports from The Business Research Company that provides neurotrophic keratitis treatment market statistics, including neurotrophic keratitis treatment industry global market size, regional shares, competitors with a neurotrophic keratitis treatment market share, detailed neurotrophic keratitis treatment market segments, market trends and opportunities and any further data you may need to thrive in the neurotrophic keratitis treatment industry. This neurotrophic keratitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurotrophic keratitis treatment market size has grown strongly in recent years. It will grow from $5.1 billion in 2024 to $5.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increased diagnoses, increasing injury and surgical procedures, rising research and development, global healthcare infrastructure.

The neurotrophic keratitis treatment market size is expected to see strong growth in the next few years. It will grow to $7.39 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to educational initiatives, increasing clinical trials, advanced therapies, regulatory approvals. Major trends in the forecast period include improved diagnostic tools, digital health solutions, neuroprotection strategies, advanced ocular surface imaging.

The increasing prevalence of eye diseases is expected to drive the growth of the neurotrophic keratitis treatment market in the coming years. Eye diseases encompass a wide range of conditions that impact the structure and function of the eyes. Neurotrophic keratitis is a condition that can help improve corneal sensation, promote healing, prevent infection, and alleviate pain. For example, in March 2022, Eye Care One, a U.S.-based eyecare career development platform, reported that an estimated 35 million people in the U.S. were affected by dry eye disease (DED) in 2022, with the prevalence expected to rise annually. Furthermore, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S. federal agency under the Department of Health and Human Services, stated that over 3.4 million Americans aged 40 and older are blind or visually impaired, a number expected to double by 2030. As a result, the growing prevalence of eye diseases is driving the expansion of the neurotrophic keratitis treatment market.

The growing investments in healthcare, particularly in eye care, are expected to drive the growth of the neurotrophic keratitis treatment market in the future. Investments in healthcare, including eye care, refer to the financial resources allocated to enhance the development, improvement, and accessibility of medical services and treatments, with a specific focus on vision-related health issues. These investments can play a pivotal role in advancing the treatment of neurotrophic keratitis, leading to breakthroughs in therapies, drug development, and ultimately improving patient outcomes and quality of life for those affected by the condition. For example, in March 2022, the Department of Health and Aged Care, an Australian government department overseeing health research and funding, reported that government investment in health systems amounted to $132 billion in 2022-23, with projections to increase to $140 billion by 2025-26, totaling $537 billion over the next four years. Therefore, the rise in healthcare investments, including in eye care, is contributing to the growth of the neurotrophic keratitis treatment market.

Major companies operating in the neurotrophic keratitis treatment market are focusing on developing innovative drugs to strengthen their market presence. Drug development is crucial in the treatment of neurotrophic keratitis, as current therapies are limited, and there is a pressing need for more effective treatments to halt disease progression. For example, in December 2022, BRIM Biotechnology Inc., a Taiwan-based clinical-stage company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug BRM424, aimed at treating neurotrophic keratitis (NK). BRM424 is a recombinant human nerve growth factor that works by stimulating the proliferation and differentiation of corneal limbal stem cells, which helps regenerate and restore the cornea's health in patients with neurotrophic keratitis. This innovative approach reflects the ongoing efforts to address the unmet medical needs in this field.

In July 2022, Regenerx Biopharmaceuticals Inc., a US-based clinical-stage drug development company, along with its joint venture and licensee partner, HLB Therapeutics Co. Ltd., a biotechnology company based in South Korea, entered into a letter of intent with a global ophthalmology contract research organization (CRO). This collaboration is focused on conducting Phase III clinical trials in the US and Europe for the treatment of neurotrophic keratitis (NK). RGN-259, a sterile and preservative-free eye drop formulation containing thymosin beta 4, a naturally occurring peptide that facilitates tissue repair and healing, is the subject of evaluation. The Phase III clinical trial will assess the efficacy and safety of RGN-259 ophthalmic solution in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathies.clinical-stage drug development company.

Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Grand Pharma Co. Ltd., Walgreen Co., Pfizer Inc., Johnson and Johnson, Bayer AG, Novartis AG, Abbott Laboratories, Gilead Biosciences Inc., Merck and Co. Inc., Allergan Inc., Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Inc., CooperVision Inc., Rohto Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Zhejiang Conba Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc., Laboratoires Thea SAS, Leadiant Biosciences Inc., ReGenTree LLC, Contacare Opthalmic Private Limited, Neuroptika Inc., Surgitech Innovation Private Limited.

North America was the largest region in the neurotrophic keratitis treatment market in 2024. The regions covered in neurotrophic keratitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurotrophic keratitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurotrophic keratitis treatment market consists of revenues earned by entities by providing services such as ophthalmic evaluation, prescription of medications, corneal neurotization, customized treatment plans, counseling and support, tarsorrhaphy and antibiotic medication supplements. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurotrophic keratitis market also includes sales of artificial tears, recombinant human nerve growth factor eye drops, antibiotics and bandage contact lenses. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurotrophic Keratitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurotrophic keratitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurotrophic keratitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurotrophic keratitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (rhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
  • 2) By Route of Administration: Oral; Topical; Other Routes of Administration
  • 3) By Application: Stage I; Stage II; Stage III
  • 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Subsegments:
  • 1) By Topical Antibiotics: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics
  • 2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution; Other rhNGF-Based Solutions
  • 3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane; Dehydrated Amniotic Membrane
  • 4) By Keratoplasty: Penetrating Keratoplasty; Lamellar Keratoplasty
  • 5) By Other Treatments: Tarsorrhaphy; Therapeutic Contact Lenses
  • Companies Mentioned: Eyevance Pharmaceuticals LLC; Grand Pharma Co. Ltd.; Walgreen Co.; Pfizer Inc.; Johnson and Johnson
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurotrophic Keratitis Treatment Market Characteristics

3. Neurotrophic Keratitis Treatment Market Trends And Strategies

4. Neurotrophic Keratitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neurotrophic Keratitis Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neurotrophic Keratitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neurotrophic Keratitis Treatment Market Growth Rate Analysis
  • 5.4. Global Neurotrophic Keratitis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neurotrophic Keratitis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neurotrophic Keratitis Treatment Total Addressable Market (TAM)

6. Neurotrophic Keratitis Treatment Market Segmentation

  • 6.1. Global Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Antibiotics
  • Recombinant Human Nerve Growth Factor (rhNGF)
  • Amniotic Membrane Transplantation
  • Keratoplasty
  • Other Treatments
  • 6.2. Global Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Topical
  • Other Routes of Administration
  • 6.3. Global Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Stage I
  • Stage II
  • Stage III
  • 6.4. Global Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users
  • 6.5. Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation Of Topical Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Broad-Spectrum Antibiotics
  • Narrow-Spectrum Antibiotics
  • 6.6. Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation Of Recombinant Human Nerve Growth Factor (rhNGF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cenegermin Ophthalmic Solution
  • Other rhNGF-Based Solutions
  • 6.7. Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation Of Amniotic Membrane Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cryopreserved Amniotic Membrane
  • Dehydrated Amniotic Membrane
  • 6.8. Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation Of Keratoplasty, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Penetrating Keratoplasty
  • Lamellar Keratoplasty
  • 6.9. Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tarsorrhaphy
  • Therapeutic Contact Lenses

7. Neurotrophic Keratitis Treatment Market Regional And Country Analysis

  • 7.1. Global Neurotrophic Keratitis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neurotrophic Keratitis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurotrophic Keratitis Treatment Market

  • 8.1. Asia-Pacific Neurotrophic Keratitis Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurotrophic Keratitis Treatment Market

  • 9.1. China Neurotrophic Keratitis Treatment Market Overview
  • 9.2. China Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurotrophic Keratitis Treatment Market

  • 10.1. India Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurotrophic Keratitis Treatment Market

  • 11.1. Japan Neurotrophic Keratitis Treatment Market Overview
  • 11.2. Japan Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurotrophic Keratitis Treatment Market

  • 12.1. Australia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurotrophic Keratitis Treatment Market

  • 13.1. Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurotrophic Keratitis Treatment Market

  • 14.1. South Korea Neurotrophic Keratitis Treatment Market Overview
  • 14.2. South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurotrophic Keratitis Treatment Market

  • 15.1. Western Europe Neurotrophic Keratitis Treatment Market Overview
  • 15.2. Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurotrophic Keratitis Treatment Market

  • 16.1. UK Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurotrophic Keratitis Treatment Market

  • 17.1. Germany Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurotrophic Keratitis Treatment Market

  • 18.1. France Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurotrophic Keratitis Treatment Market

  • 19.1. Italy Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurotrophic Keratitis Treatment Market

  • 20.1. Spain Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurotrophic Keratitis Treatment Market

  • 21.1. Eastern Europe Neurotrophic Keratitis Treatment Market Overview
  • 21.2. Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurotrophic Keratitis Treatment Market

  • 22.1. Russia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurotrophic Keratitis Treatment Market

  • 23.1. North America Neurotrophic Keratitis Treatment Market Overview
  • 23.2. North America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurotrophic Keratitis Treatment Market

  • 24.1. USA Neurotrophic Keratitis Treatment Market Overview
  • 24.2. USA Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurotrophic Keratitis Treatment Market

  • 25.1. Canada Neurotrophic Keratitis Treatment Market Overview
  • 25.2. Canada Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurotrophic Keratitis Treatment Market

  • 26.1. South America Neurotrophic Keratitis Treatment Market Overview
  • 26.2. South America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurotrophic Keratitis Treatment Market

  • 27.1. Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurotrophic Keratitis Treatment Market

  • 28.1. Middle East Neurotrophic Keratitis Treatment Market Overview
  • 28.2. Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurotrophic Keratitis Treatment Market

  • 29.1. Africa Neurotrophic Keratitis Treatment Market Overview
  • 29.2. Africa Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurotrophic Keratitis Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Neurotrophic Keratitis Treatment Market Competitive Landscape
  • 30.2. Neurotrophic Keratitis Treatment Market Company Profiles
    • 30.2.1. Eyevance Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Grand Pharma Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Walgreen Co. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis

31. Neurotrophic Keratitis Treatment Market Other Major And Innovative Companies

  • 31.1. Bayer AG
  • 31.2. Novartis AG
  • 31.3. Abbott Laboratories
  • 31.4. Gilead Biosciences Inc.
  • 31.5. Merck and Co. Inc.
  • 31.6. Allergan Inc.
  • 31.7. Alcon Inc.
  • 31.8. Bausch Health Companies Inc.
  • 31.9. Bausch & Lomb Inc.
  • 31.10. CooperVision Inc.
  • 31.11. Rohto Pharmaceutical Co. Ltd.
  • 31.12. Santen Pharmaceutical Co. Ltd.
  • 31.13. Zhejiang Conba Pharmaceutical Co. Ltd.
  • 31.14. Glenmark Pharmaceuticals Limited
  • 31.15. Dompe farmaceutici S.p.A

32. Global Neurotrophic Keratitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurotrophic Keratitis Treatment Market

34. Recent Developments In The Neurotrophic Keratitis Treatment Market

35. Neurotrophic Keratitis Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Neurotrophic Keratitis Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neurotrophic Keratitis Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neurotrophic Keratitis Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer